What can Parkinson's disease teach us about COVID-19?

Neurol Neurochir Pol. 2020;54(2):204-206. doi: 10.5603/PJNNS.a2020.0039. Epub 2020 Apr 23.

Authors

Philip W Tipton¹, Zbigniew K Wszolek²

Affiliations

¹ Department of Neurology, Mayo Clinic Florida, Jacksonville, USA. tipton.philip@mayo.edu.
² Department of Neurology, Mayo Clinic Florida, Jacksonville, USA.

PMID: 32323862
DOI: 10.5603/PJNNS.a2020.0039

No abstract available

Keywords: COVID-19; Parkinson’s disease; amantadine; memantine.

MeSH terms

Antiparkinson Agents
Betacoronavirus*
COVID-19
Coronavirus Infections / complications*
Humans
Levodopa
Pandemics
Parkinson Disease* / complications
Pneumonia, Viral / complications*
SARS-CoV-2

Substances

Antiparkinson Agents
Levodopa